Anthropic’s IPO filing disclosed plans to expand life sciences work, including investment in knowledge, talent, partnerships, and additional acquisitions. The company also described building AI agents based on Claude that go beyond drug discovery to support physical tasks associated with creating therapies. Anthropic’s Form S-1 highlighted its Model Hardware Standard in research preview, describing safe operation of lab and manufacturing equipment such as microscopes, liquid handlers, and robotic arms. The filing also pointed to life-sciences lab activity as part of the route to profitability. While details on specific therapy areas were limited in the disclosure, the document positions Anthropic as moving deeper into wet-lab-adjacent workflows.